A detailed history of Gallacher Capital Management LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Gallacher Capital Management LLC holds 2,180 shares of BNTX stock, worth $217,389. This represents 0.12% of its overall portfolio holdings.

Number of Shares
2,180
Previous 3,657 40.39%
Holding current value
$217,389
Previous $294 Million 11.9%
% of portfolio
0.12%
Previous 0.15%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$78.36 - $124.66 $115,737 - $184,122
-1,477 Reduced 40.39%
2,180 $259 Million
Q2 2024

Aug 06, 2024

BUY
$80.36 - $102.87 $31,742 - $40,633
395 Added 12.11%
3,657 $294 Million
Q1 2024

May 06, 2024

BUY
$88.96 - $112.35 $57,112 - $72,128
642 Added 24.5%
3,262 $301 Million
Q4 2023

Feb 06, 2024

BUY
$90.91 - $112.75 $57,273 - $71,032
630 Added 31.66%
2,620 $277 Million
Q3 2023

Nov 13, 2023

BUY
$98.5 - $125.08 $196,015 - $248,909
1,990 New
1,990 $216 Million

Others Institutions Holding BNTX

About BioNTech SE


  • Ticker BNTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 242,684,992
  • Market Cap $24.2B
  • Description
  • BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...
More about BNTX
Track This Portfolio

Track Gallacher Capital Management LLC Portfolio

Follow Gallacher Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gallacher Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gallacher Capital Management LLC with notifications on news.